Last close As at 06/08/2026
—
— 0.00 (0.00%)
Market capitalisation
—
Research: TMT
Doctor Care Anywhere Group’s (DOC’s) Q121 update showed that it continues to grow robustly in 2021, with revenue and consultations up c 260% y-o-y, ending the period with a solid balance sheet (net cash of £35.1m). Management remains confident of the growth potential for the rest of the year and expects revenue in 2021 to grow by at least 100% above 2020 levels. We have upgraded our FY21 forecasts following a robust Q1 and the company’s upbeat outlook for 2021.
Written by
Doctor Care Anywhere Group |
Forecast upgrade following solid Q1 performance |
Q1 trading update |
Healthcare equipment & services |
29 April 2021 |
Share price performance
Business description
Next events
Analysts
Doctor Care Anywhere Group is a research client of Edison Investment Research Limited |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Doctor Care Anywhere Group’s (DOC’s) Q121 update showed that it continues to grow robustly in 2021, with revenue and consultations up c 260% y-o-y, ending the period with a solid balance sheet (net cash of £35.1m). Management remains confident of the growth potential for the rest of the year and expects revenue in 2021 to grow by at least 100% above 2020 levels. We have upgraded our FY21 forecasts following a robust Q1 and the company’s upbeat outlook for 2021.
Year end |
Revenue (£m) |
PBT* |
EPS* |
DPS |
EV/Sales |
P/E |
12/19 |
5.7 |
(4.4) |
(3.7) |
0.0 |
24.6 |
N/A |
12/20 |
11.6 |
(13.5) |
(7.8) |
0.0 |
12.1 |
N/A |
12/21e |
23.4 |
(16.3) |
(5.1) |
0.0 |
6.0 |
N/A |
12/22e |
37.4 |
(9.0) |
(2.8) |
0.0 |
3.8 |
N/A |
Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.
Solid Q1 revenue and KPI growth
Underlying revenue (excluding £2m one-off revenue) was up 260% y-o-y to £4.4m in Q121, resulting from 261% y-o-y growth in consultations. Eligible lives increased 39% y-o-y to 2.38m at the end of Q121, already beating our H121 2.25m forecast and underlying the pace at which DOC has grown in Q1. Activated lives at the end of Q121 increased by 183% y-o-y to 495.9k, with DOC remaining comfortably on track to meet our 505.3k forecast for H121. DOC ended Q121 with a robust net cash position of £35.1m (£38.4m at the end of 2020).
Robust growth to continue in 2021
Management is confident of DOC’s growth potential for the rest of 2021 and expects group revenue to grow by at least 100% above 2020 levels, implying at least £23.2m in group revenue in 2021. With pressure on an already embattled UK healthcare system expected to continue, the company anticipates demand for its GP consultations (primary care) to remain high. Additionally, it expects the easing of lockdown in the UK to accelerate growth for its secondary care services.
2021 forecast updated, 2022 largely unchanged
Our updated 2021 revenue forecast now stands 9% higher at £23.4m (£21.4m previously), as we factor in £2m in one-off revenue in Q121. The higher revenue forecast results in gross profitability increasing by 22% to £11.2m (£9.2m previously), which translates into a 9% decline in net loss to £16.2m (£17.8m previously) and our net cash forecast being boosted by 8% to £20.9m (£19.4m previously). The only change to our 2022 forecast is that our net cash position now stands 25% higher at £7.8m (versus £6.3m previously) due to a higher forecast net cash position at the start of the year.
Valuation: Significant discount to peer group
DOC trades at 6x our updated 2021 revenue forecast on an EV/Sales multiple, a 65% discount to the 17.2x average of its peer group of global telehealth companies. We believe this valuation discount to peers will reduce over the next 12–18 months, as DOC builds up a track record on the market and executes on its growth strategy.
Robust growth continued in Q121
DOC’s Q121 activity report showed that it continued to grow solidly, with revenue and KPIs increasing robustly.
Financial performance
Group revenue increased 69% q-o-q and 242% y-o-y to £6.4m in Q121, resulting from 22% quarter-on-quarter and 261% y-o-y growth in the number of consultations during the period. We do not forecast quarterly numbers. Underlying revenue at £4.4m in Q121 was up 17% q-o-q and 260% y-o-y. The £2m difference in underlying revenue versus group revenue is due to one-off revenue earned by DOC, related to incentive payments and payments for technology development. Underlying revenue of £4.4m for Q121 equates to 48% of our £9.1m H121 group revenue forecast for DOC.
Gross profit in Q121 was up 120% q-o-q and 215% y-o-y to £3.9m, benefiting from solid consultation-led revenue growth in the period. However, gross margin declined by 14.2pp q-o-q and 5.3pp y-o-y to 61%, as a result of higher than expected demand for DOC’s services and increased demand on GPs to deliver the national vaccine roll-out in the UK. The company expects this dip in gross margins to be temporary. Underlying gross profit was up 8% q-o-q and 222% y-o-y to £1.9m, equating to 49% of our H121 gross profit forecast of £3.9m. This resulted in an underlying gross margin of 43.2%, down 3.6pp q-o-q and 5.2pp y-o-y, but in line with our gross margin forecast at 43.3% for H121.
DOC ended Q121 with a solid net cash position of £35.1m versus £38.4m net cash at the end of 2020. The net cash burn of £3.3m resulted from net operating cash outflow of £2.4m in Q121, net investing cash outflow of £0.7m and net cash outflow from financing of £0.2m. DOC’s £35.1m net cash position at the end of Q121 puts it comfortably ahead of our £29.2m forecast for H121 period end, implying that DOC could spend another £5.9m in Q221 and be in line with our forecast.
Exhibit 1: DOC Q1 results summary
£m |
Q121 |
Q420 |
Q-o-q chg. |
Q120 |
Y-o-y chg. |
Revenue |
6.4 |
3.8 |
69% |
1.9 |
242% |
Gross profit |
3.9 |
1.8 |
120% |
1.2 |
215% |
Gross margin |
61.0% |
46.8% |
14pp |
66.3% |
-5pp |
Contribution |
2.9 |
0.9 |
236% |
0.9 |
223% |
Contribution margin |
45.0% |
22.7% |
22pp |
22.7% |
22pp |
Underlying basis* |
|||||
Revenue |
4.4 |
3.8 |
17% |
1.2 |
260% |
Gross profit |
1.9 |
1.8 |
8% |
0.6 |
222% |
Gross margin |
43.2% |
46.8% |
-4pp |
48.4% |
-5pp |
Contribution |
2.9 |
0.9 |
236% |
0.9 |
223% |
Contribution margin |
20.0% |
22.6% |
-3pp |
20.0% |
- |
Source: Company data; *Excludes one-off revenue such as underwritten volume top-up payments, tech platform licensing fees and digital design service fees.
Operational performance
Eligible Lives (2.38m at Q121 end; +7% q-o-q and +39% y-o-y)
Eligible Lives refers to the total number of customers across all its partners, who are entitled to use DOC's services at the end of a given period. The partners need to onboard their customers onto the platform once.
Eligible lives increased 7% q-o-q and 39% y-o-y to 2.38m at the end of Q121, benefiting from growth across both established channel partners and new partner Allianz. We note that eligible lives at 2.38m at the end of Q121 are already 6% ahead of our H121 2.25m forecast, underlying the pace at which DOC has grown in the first quarter of the year.
Activated Lives (495.9k at Q1 21 end; +15% q-o-q and +183% y-o-y)
Activated Lives refers to the total number of eligible lives who have signed up for DOC's service at the end of a given period.
Activated lives at the end of Q121 increased 15% q-o-q and 183% y-o-y to 495.9k, resulting from growth across both eligible lives and previously eligible customers signing up during the period. DOC remains comfortably on track to meet our H121 activated lives forecast of 505.3k.
|
Exhibit 2: Activated lives (000s) at period end |
Exhibit 3: Consultations (000s) |
|
|
|
Source: Company data |
Source: Company data |
|
Exhibit 2: Activated lives (000s) at period end |
|
|
Source: Company data |
|
Exhibit 3: Consultations (000s) |
|
|
Source: Company data |
Consultations (90.5k, +22% q-o-q and +261% y-o-y)
Consultations are the number of Video GP (VGP) consultations delivered to patients during a given period.
Consultations in Q121 grew solidly to 90.5k, an increase of 22% q-o-q and 261% y-o-y. The key drivers for a robust increase in consultations during the period were growth in activated lives and growth in annualised utilisation (consultations divided by average activated lives during the period). In March 2021 alone, DOC delivered 34k consultations (38% of total consultations in Q121), which was 32% higher than the best month in Q420. DOC’s Q121 consultations at 90.5k are equivalent to 49% of our consultations forecast for H121.
Robust outlook: 2021 revenue to increase by at least 100% y-o-y
After a solid Q1, management is confident of the group’s growth potential for the rest of 2021. DOC expects 2021 revenue to grow by at least 100% above 2020 levels (£11.6m), driven by eligible lives, activations and consultations, along with areas like secondary care, whose growth was curtailed by COVID-19-related lockdowns. This implies that 2021 revenue would be at least at £23.2m, 8% ahead of our prior forecast of £21.4m.
With pressure on an already embattled UK healthcare system expected to continue, DOC anticipates demand for its GP consultations (primary care) to remain high. According to data provided by the company, waiting times to see a GP in the UK can be as much as three weeks versus a mere four to eight hours for DOC’s VGP service. Additionally, the company expects the easing of lockdown measures in the UK to accelerate growth for its Internet Hospital secondary care services.
2021 forecast tweaked, 2022 largely unchanged
We have updated our forecasts for DOC to factor in the £2m one-off revenue earned in Q121. Our updated 2021 group revenue forecast is now 9% higher at £23.4m (versus £21.4m previously). The upgraded group revenue forecast results in gross profitability increasing by 22% to £11.2m (£9.2m previously), which leads to a 4.9pp higher gross margin at 47.7% (versus 42.9% previously). This translates into a 9% lower EBITDA loss in 2021 at £15.5m (£17.1m previously) and a 9% decline in net loss to £16.2m (£17.8m previously). The lower net loss in 2021 leads to our net cash forecast being boosted by 8% to £20.9m (£19.4m prior).
Exhibit 4: DOC forecast change summary
£000s |
Current estimates |
Prior estimates |
Change |
|||
2021e |
2022e |
2021e |
2022e |
2021 chg. |
2022 chg. |
|
Revenues |
23,405 |
37,432 |
21,405 |
37,432 |
9% |
0% |
Gross Profit |
11,175 |
15,564 |
9,175 |
15,564 |
22% |
0% |
Gross Margin |
47.7% |
41.6% |
42.9% |
41.6% |
488bp |
0bp |
EBITDA |
(15,512) |
(11,386) |
(17,062) |
(11,386) |
-9% |
0% |
Operating profit (EBIT) |
(16,581) |
(12,616) |
(18,131) |
(12,616) |
-9% |
0% |
Share of JV gain/ (loss) |
319 |
3,660 |
319 |
3,660 |
0% |
0% |
Net profit |
(16,235) |
(8,938) |
(17,783) |
(8,938) |
-9% |
0% |
Basic EPS (pence) |
(5.09) |
(2.80) |
(5.58) |
(2.80) |
-9% |
0% |
Diluted shares outstanding ('000) |
318,720 |
318,720 |
318,720 |
318,720 |
0% |
0% |
Diluted EPS (pence) |
(5.09) |
(2.80) |
(5.58) |
(2.80) |
-9% |
0% |
Net cash |
20,898 |
7,845 |
19,350 |
6,297 |
8% |
25% |
Operational data |
|
|
|
|
|
|
Eligible lives at period end ('000) |
2,384.7 |
2,635.3 |
2,384.7 |
2,635.3 |
0% |
0% |
Activated lives at period end ('000) |
596.2 |
724.7 |
596.2 |
724.7 |
0% |
0% |
Consultations ('000) |
431.8 |
757.0 |
431.8 |
757.0 |
0% |
0% |
Source: Edison Investment Research
We make no changes to our revenue forecast for 2022 and, as a result, our 2022 profitability forecast remains unchanged. The only change to our 2022 forecast is our net cash forecast for DOC now stands 25% higher at £7.8m (versus £6.3m previously) due to a higher net cash position at the start of the year, resulting from our 2021 revenue forecast upgrade.
Valuation unchanged
We continue to value DOC against a peer group of global telehealth companies. In our 8 April 2021 initiation note, we valued DOC on an EV/sales multiple of 13.8x, a 20% discount to the peer multiple of 17.2x to account for 1) a smaller company valuation discount and 2) a lack of track record on the market compared to the peer group.
Applying this 13.8x EV/sales multiple and excluding the £2m in one-off revenue the company earned in Q121 results in our valuation for DOC remaining unchanged at an EV of £277m/A$499m,1 which equates to A$1.73 (£0.96) per share, 71% above the current share price of A$1.01.
A$1.7992/£
Exhibit 5: Financial summary
£m |
2018 |
2019 |
2020 |
2021e |
2022e |
||
Year end 31 December |
IFRS |
IFRS |
IFRS |
IFRS |
IFRS |
||
INCOME STATEMENT |
|||||||
Revenue |
|
|
2.0 |
5.7 |
11.6 |
23.4 |
37.4 |
Cost of Sales |
(0.8) |
(1.4) |
(5.9) |
(12.2) |
(21.9) |
||
Gross Profit |
1.2 |
4.4 |
5.7 |
11.2 |
15.6 |
||
EBITDA |
|
|
(4.1) |
(3.8) |
(7.8) |
(15.5) |
(11.4) |
Normalised operating profit |
|
|
(5.1) |
(4.5) |
(4.9) |
(16.6) |
(12.6) |
Amortisation of acquired intangibles |
- |
- |
- |
- |
- |
||
Exceptionals |
0.0 |
0.0 |
6.0 |
- |
- |
||
Share-based payments |
0.0 |
(0.1) |
(2.2) |
- |
- |
||
Reported operating profit |
(5.1) |
(4.5) |
(8.7) |
(16.6) |
(12.6) |
||
Net Interest |
(0.0) |
(0.0) |
(0.1) |
- |
- |
||
Joint ventures & associates (post tax) |
- |
0.0 |
(0.8) |
0.3 |
3.7 |
||
Exceptionals |
- |
(1.3) |
(21.7) |
- |
- |
||
Profit Before Tax (norm) |
|
|
(5.2) |
(4.4) |
(13.5) |
(16.3) |
(9.0) |
Profit Before Tax (reported) |
|
|
(5.1) |
(5.8) |
(31.4) |
(16.3) |
(9.0) |
Reported tax |
0.1 |
0.1 |
0.1 |
0.0 |
0.0 |
||
Profit After Tax (norm) |
(5.0) |
(4.4) |
(13.4) |
(16.2) |
(8.9) |
||
Profit After Tax (reported) |
(5.0) |
(5.7) |
(31.3) |
(16.2) |
(8.9) |
||
Minority interests |
- |
- |
- |
- |
- |
||
Discontinued operations |
- |
- |
- |
- |
- |
||
Net income (normalised) |
(5.0) |
(4.4) |
(13.4) |
(16.2) |
(8.9) |
||
Net income (reported) |
(5.0) |
(5.7) |
(31.3) |
(16.2) |
(8.9) |
||
Basic average number of shares outstanding (m) |
116.4 |
117.4 |
171.9 |
318.7 |
318.7 |
||
EPS - basic normalised (p) |
|
|
(4.31) |
(3.71) |
(7.81) |
(5.09) |
(2.80) |
EPS - diluted normalised (p) |
|
|
(4.31) |
(3.71) |
(7.81) |
(5.09) |
(2.80) |
EPS - basic reported (p) |
|
|
(4.28) |
(4.83) |
(18.20) |
(5.09) |
(2.80) |
Dividend (p) |
- |
- |
- |
- |
- |
||
Revenue growth (%) |
N/A |
184.2 |
102.1 |
102.2 |
59.9 |
||
Gross Margin (%) |
58.0 |
76.1 |
49.2 |
47.7 |
41.6 |
||
EBITDA Margin (%) |
-204.7 |
-66.0 |
-67.3 |
-66.3 |
-30.4 |
||
Normalised Operating Margin |
-252.5 |
-78.8 |
-41.9 |
-70.8 |
-33.7 |
||
BALANCE SHEET |
|||||||
Fixed Assets |
|
|
3.0 |
3.8 |
7.5 |
8.8 |
13.3 |
Intangible Assets |
2.8 |
3.6 |
3.6 |
4.5 |
5.3 |
||
Tangible Assets |
0.1 |
0.3 |
1.7 |
1.8 |
1.8 |
||
Investments & other |
0.0 |
0.0 |
2.2 |
2.5 |
6.2 |
||
Current Assets |
|
|
2.3 |
1.2 |
42.0 |
27.6 |
19.6 |
Stocks |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
||
Debtors |
0.6 |
0.6 |
3.6 |
6.7 |
11.7 |
||
Cash & cash equivalents |
1.7 |
0.6 |
38.4 |
20.9 |
7.8 |
||
Other |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
||
Current Liabilities |
|
|
(2.0) |
(2.1) |
(3.8) |
(7.0) |
(12.4) |
Creditors |
(2.0) |
(2.1) |
(3.8) |
(7.0) |
(12.4) |
||
Tax and social security |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
||
Short term borrowings |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
||
Other |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
||
Long Term Liabilities |
|
|
(2.9) |
(8.2) |
(1.2) |
(1.2) |
(1.2) |
Long term borrowings |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
||
Other long-term liabilities |
(2.9) |
(8.2) |
(1.2) |
(1.2) |
(1.2) |
||
Net Assets |
|
|
0.4 |
(5.4) |
44.5 |
28.2 |
19.3 |
Minority interests |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
||
Shareholders' equity |
|
|
0.4 |
(5.4) |
44.5 |
28.2 |
19.3 |
CASH FLOW |
|||||||
Op Cash Flow before WC and tax |
(5.1) |
(4.4) |
(12.5) |
(16.6) |
(12.6) |
||
Working capital |
1.0 |
0.3 |
(1.2) |
0.1 |
0.4 |
||
Exceptional & other |
1.1 |
0.9 |
3.2 |
1.1 |
1.2 |
||
Tax |
0.1 |
(0.1) |
(0.0) |
0.0 |
0.0 |
||
Net operating cash flow |
|
|
(2.8) |
(3.3) |
(10.7) |
(15.4) |
(11.0) |
Capex |
(1.0) |
(1.7) |
(1.8) |
(2.1) |
(2.1) |
||
Acquisitions/disposals |
0.0 |
0.0 |
3.0 |
0.0 |
0.0 |
||
Net interest |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
||
Equity financing |
0.0 |
0.2 |
31.2 |
0.0 |
0.0 |
||
Dividends |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
||
Other |
2.7 |
3.8 |
16.0 |
0.0 |
0.0 |
||
Net Cash Flow |
(1.1) |
(1.1) |
37.8 |
(17.5) |
(13.1) |
||
Opening net debt/(cash) |
|
|
(2.8) |
(1.7) |
(0.6) |
(38.4) |
(20.9) |
FX |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
||
Other non-cash movements |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
||
Closing net debt/(cash) |
|
|
(1.7) |
(0.6) |
(38.4) |
(20.9) |
(7.8) |
Source: Company data, Edison Investment Research
|
|
Research: Energy & Resources
Egdon Resources’ core focus is on its conventional assets, and the commencement of oil flow at Wressle was the most significant event for the six months to 31 January 2021. The company is targeting 150boed net here, pending further activity. Production during the period was 92boed, down from 178boed in H120 and guidance for FY21 is 110–130boed. Further planned onshore drilling will depend on successful farm-outs, while offshore, the 2020 farm-out of the Resolution and Endeavour gas discoveries to Shell will fund a 3D seismic survey, though this has slipped into 2022. Egdon is also screening geothermal opportunities, and signed an MoU with Creative Geothermal Solutions (CGS) to facilitate progress both within Egdon’s portfolio and beyond.